AZD-9291 mesylate Size:Solid 10 mg 74(6):897-905

74(6):897-905

TBB is an ATP/GTP competitive inhibitor of protein kinase casein kinase-2 (CK2)

Compared with placebo-treated animals

Dose escalation of MK-8776 S-isomer (16 mg/kg and 32 mg/kg) induces incremental improvements in tumor response

but not impairing the primary immune response in allergic contact dermatitis in mice

AZD-9291 mesylate Size:Solid 10 mg 74(6):897-905Osimertinib, also known as AZD 9291 and Mereletinib, is a third generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors. AZD9291 is highly active in preclinical models and is well tolerated in animal models. It inhibits both activating and resistant EGFR mutations while sparing the normal form of EGFR that is present in normal skin